Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT ID: NCT04195698

Last Updated: 2025-01-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

475 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-15

Study Completion Date

2023-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed.

Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Upadacitinib

Participants will be administered with upadacitinib once daily (QD)

Group Type EXPERIMENTAL

Upadacitinib

Intervention Type DRUG

Upadacitinib will be administered oral as tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Upadacitinib

Upadacitinib will be administered oral as tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-494 RINVOQ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants should have successfully completed treatment in the M16-046 study, without meeting any permanent discontinuation criteria.
* Participant is judged to be in general good health (other than AD) as determined by the Principal Investigator and remains eligible as per the criteria for the study M16-046 to continue treatment in the long term extension study.

Exclusion Criteria

* Requirement of prohibited medications during the study treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
* Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Sciences /ID# 221021

Little Rock, Arkansas, United States

Site Status

Duplicate_First OC Dermatology Research Inc /ID# 218619

Fountain Valley, California, United States

Site Status

UCSF Fresno /ID# 218453

Fresno, California, United States

Site Status

California Allergy and Asthma Medical Group /ID# 218635

Los Angeles, California, United States

Site Status

Dermatology Research Associates /ID# 218637

Los Angeles, California, United States

Site Status

Dermatology Clinical Trials /ID# 218627

Newport Beach, California, United States

Site Status

Duplicate_UC Davis Health /ID# 218582

Sacramento, California, United States

Site Status

Ucsd /Id# 218629

San Diego, California, United States

Site Status

Clinical Science Institute /ID# 218632

Santa Monica, California, United States

Site Status

Miami Dermatology and Laser Institute /ID# 218664

Miami, Florida, United States

Site Status

Florida International Rsrch cr /ID# 218663

Miami, Florida, United States

Site Status

GCP Research /ID# 218665

St. Petersburg, Florida, United States

Site Status

Clinical Research Trials of Florida, Inc. /ID# 218438

Tampa, Florida, United States

Site Status

Georgia Pollens Clinical Research Centers, Inc /ID# 218441

Albany, Georgia, United States

Site Status

Medical Dermatology Associates of Chicago /ID# 218551

Chicago, Illinois, United States

Site Status

Sneeze, Wheeze, & Itch Associates, LLC /ID# 218552

Normal, Illinois, United States

Site Status

Dawes Fretzin, LLC /ID# 218478

Indianapolis, Indiana, United States

Site Status

Beacon Clinical Research, LLC /ID# 218636

Quincy, Massachusetts, United States

Site Status

Duplicate_Michigan Center for Research Company /ID# 218577

Clarkston, Michigan, United States

Site Status

Henry Ford Medical Center - New Center One /ID# 218575

Detroit, Michigan, United States

Site Status

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548

Lincoln, Nebraska, United States

Site Status

Skin Specialists, PC /ID# 218549

Omaha, Nebraska, United States

Site Status

University Hospitals Case Medical Center /ID# 218574

Cleveland, Ohio, United States

Site Status

Southside Dermatology /ID# 218477

Tulsa, Oklahoma, United States

Site Status

Oregon Medical Research Center /ID# 218440

Portland, Oregon, United States

Site Status

Oregon Medical Research Center /ID# 218578

Portland, Oregon, United States

Site Status

Duplicate_Medical University of South Carolina /ID# 221072

Charleston, South Carolina, United States

Site Status

Clinical Research Solutions, LLC /ID# 218447

Jackson, Tennessee, United States

Site Status

Orion Clinical Research /ID# 218565

Austin, Texas, United States

Site Status

Sante Clinical Research /ID# 218911

Kerrville, Texas, United States

Site Status

Clinical Research Partners, LLC /ID# 218480

Richmond, Virginia, United States

Site Status

Duplicate_Premier Clinical Research /ID# 218583

Spokane, Washington, United States

Site Status

West Virginia Research Inst /ID# 218479

South Charleston, West Virginia, United States

Site Status

Holdsworth House Medical Practice /ID# 218755

Darlinghurst, New South Wales, Australia

Site Status

The Skin Hospital /ID# 218753

Darlinghurst, New South Wales, Australia

Site Status

Veracity Clinical Research /ID# 218754

Woolloongabba, Queensland, Australia

Site Status

Sinclair Dermatology - Melbourne /ID# 218751

East Melbourne, Victoria, Australia

Site Status

Burswood Dermatology /ID# 218752

Victoria Park, Western Australia, Australia

Site Status

Kirk Barber Research, CA /ID# 218727

Calgary, Alberta, Canada

Site Status

Duplicate_Dermatology Research Institute Inc. /ID# 218728

Calgary, Alberta, Canada

Site Status

Dr. Chih-ho Hong Medical Inc. /ID# 218725

Surrey, British Columbia, Canada

Site Status

Enverus Medical Research /ID# 218726

Surrey, British Columbia, Canada

Site Status

Dr. Wei Jing Loo Medicine Prof /ID# 218722

London, Ontario, Canada

Site Status

Duplicate_Lynderm Research Inc. /ID# 218723

Markham, Ontario, Canada

Site Status

DermEdge Research Inc. /ID# 218721

Mississauga, Ontario, Canada

Site Status

North York Research Inc /ID# 218729

Toronto, Ontario, Canada

Site Status

Duplicate_K. Papp Clinical Research /ID# 218730

Waterloo, Ontario, Canada

Site Status

Dre Angelique Gagne-Henley M.D. inc. /ID# 218724

Saint-Jérôme, Quebec, Canada

Site Status

DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 218377

Zagreb, City of Zagreb, Croatia

Site Status

Klinicki bolnicki centar Zagreb /ID# 218375

Zagreb, City of Zagreb, Croatia

Site Status

Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 218376

Ivanić-Grad, Zagreb County, Croatia

Site Status

Fakultni nemocnice Hradec Kralove /ID# 214176

Hradec Králové, , Czechia

Site Status

Nemocnice Jihlava, prispevkova organizace /ID# 214178

Jihlava, , Czechia

Site Status

Fakultni Nemocnice Ostrava /ID# 214177

Ostrava, , Czechia

Site Status

Duplicate_Duplicate_Fakultni Nemocnice v Motole /ID# 214179

Prague, , Czechia

Site Status

Keski-pohjanmaa Central Hospital /ID# 214630

Kokkola, Keski-Pohjanmaa, Finland

Site Status

Duplicate_Oulun yliopistollinen sairaala /ID# 214628

Oulu, North Ostrobothnia, Finland

Site Status

Mikkeli Central Hospital /ID# 214629

Mikkeli, , Finland

Site Status

AP-HM - Hopital de la Timone /ID# 218957

Marseille, Bouches-du-Rhone, France

Site Status

Polyclinique Courlancy /ID# 218955

Reims, Marne, France

Site Status

CHU de Nantes, Hotel Dieu -HME /ID# 218959

Nantes, Pays de la Loire Region, France

Site Status

Hôpital Charles-Nicolle /ID# 218960

Rouen, , France

Site Status

CHU Toulouse - Hopital Larrey /ID# 218958

Toulouse, , France

Site Status

Dermatologische Mahlow /ID# 214225

Blankenfelde-Mahlow, Brandenburg, Germany

Site Status

Duplicate_Klinikum Darmstadt GmbH /ID# 214224

Darmstadt, Hesse, Germany

Site Status

Universitaetsklinikum Frankfurt /ID# 214223

Frankfurt am Main, Hesse, Germany

Site Status

Duplicate_Universitaetsklinikum Muenster /ID# 214222

Munster, Lower Saxony, Germany

Site Status

Medizinische Hochschule Hannover /ID# 214226

Hanover, , Germany

Site Status

Duplicate_Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 214221

Munich, , Germany

Site Status

Oroshazi Korhaz /ID# 214986

Orosháza, Bekes County, Hungary

Site Status

Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 214984

Kaposvár, Somogy County, Hungary

Site Status

Uno Medical Trials Kft /ID# 214987

Budapest, , Hungary

Site Status

St Vincent's University Hospital /ID# 213558

Elm Park, Dublin, Ireland

Site Status

Duplicate_HaEmek Medical Center /ID# 218520

Afula, Southern District, Israel

Site Status

The Chaim Sheba Medical Center /ID# 218522

Ramat Gan, Tel Aviv, Israel

Site Status

Rabin Medical Center /ID# 218521

Haifa, , Israel

Site Status

Istituto Clinico Humanitas /ID# 215727

Rozzano, Milano, Italy

Site Status

Fondazione PTV Policlinico Tor Vergata /ID# 214093

Rome, Roma, Italy

Site Status

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214095

Milan, , Italy

Site Status

Azienda Ospedaliero-Universitaria di Modena /ID# 214096

Modena, , Italy

Site Status

Hospital Sultan Ismail /ID# 218881

Johor Bahru, Johor, Malaysia

Site Status

Hospital Pakar Sultanah Fatimah /ID# 218877

Muar town, Johor, Malaysia

Site Status

Hospital Putrajaya /ID# 218880

Putrajaya, Putrajaya, Malaysia

Site Status

Universiti Kebangsaan Malaysia (UKM) Medical Centre /ID# 218879

Kuala Lumpur, Selangor, Malaysia

Site Status

Hospital Pulau Pinang /ID# 218878

George Town, , Malaysia

Site Status

University Malaya Med Ctr /ID# 218882

Kuala Lumpur, , Malaysia

Site Status

Bravis Ziekenhuis /ID# 218772

Bergen op Zoom, North Brabant, Netherlands

Site Status

Duplicate_Erasmus Medisch Centrum /ID# 218770

Rotterdam, South Holland, Netherlands

Site Status

Universitair Medisch Centrum Groningen /ID# 218775

Groningen, , Netherlands

Site Status

Universitair Medisch Centrum Utrecht /ID# 218771

Utrecht, , Netherlands

Site Status

Optimal Clinical Trials Ltd /ID# 218688

Grafotn, Auckland, New Zealand

Site Status

Wellington Regional Hospital /ID# 218689

Newtown, Wellington Region, New Zealand

Site Status

Clinical Trials New Zealand /ID# 218690

Hamilton, , New Zealand

Site Status

Duplicate_Universitetssykehuset N-Norge, Tromso /ID# 214634

Tromsø, Troms, Norway

Site Status

Duplicate_Pratia MCM Krakow /ID# 214303

Krakow, Lesser Poland Voivodeship, Poland

Site Status

Klinika Ambroziak Sp. z o.o. /ID# 214301

Warsaw, Masovian Voivodeship, Poland

Site Status

Duplicate_Duplicate_Royalderm Agnieszka Nawrocka /ID# 214302

Warsaw, Masovian Voivodeship, Poland

Site Status

ClinicMed Daniluk, Nowak Sp.k. /ID# 214299

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Dermoklinika Centrum Medyczne s.c. /ID# 214300

Lodz, Łódź Voivodeship, Poland

Site Status

National University Hospital /ID# 219093

Singapore, , Singapore

Site Status

Duplicate_Hospital Universitario de Bellvitge /ID# 214257

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital Universitario Dr. Negrin /ID# 214256

Las Palmas de Gran Canaria, Las Palmas, Spain

Site Status

Hospital de Manises /ID# 214258

Manises, Valencia, Spain

Site Status

Complejo Hospitalario Universitario de Pontevedra /ID# 214255

Pontevedra, , Spain

Site Status

Hospital Universitario Arnau Vilanova /ID# 214254

Valencia, , Spain

Site Status

Hospital Universitario y Politecnico La Fe /ID# 214252

Valencia, , Spain

Site Status

National Taiwan University Hospital /ID# 218917

Taipei City, Taipei, Taiwan

Site Status

Chung Shan Medical University Hospital /ID# 218919

Taichung, , Taiwan

Site Status

China Medical University Hospital /ID# 218409

Taichung, , Taiwan

Site Status

Taipei Municipal Wan Fang Hospital /ID# 218918

Taipei, , Taiwan

Site Status

Kyiv City Clinical Skin and Venereal Hospital /ID# 218382

Kyiv, Kyivska Oblast, Ukraine

Site Status

ME "Rivne Regional Dermatology and Venereology Dispensary" of RRC /ID# 218385

Rivne, , Ukraine

Site Status

Victoria Hospital /ID# 213564

Kirkcaldy, Fife, United Kingdom

Site Status

Duplicate_The Royal Free London NHS Foundation Trust /ID# 213560

London, London, City of, United Kingdom

Site Status

NHS Greater Glasgow and Clyde /ID# 213561

Glasgow, Scotland, United Kingdom

Site Status

University Hospitals Sussex NHS Foundation Trust /ID# 213562

Worthing, West Sussex, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Croatia Czechia Finland France Germany Hungary Ireland Israel Italy Malaysia Netherlands New Zealand Norway Poland Singapore Spain Taiwan Ukraine United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.rxabbvie.com

This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M19-850

Identifier Type: -

Identifier Source: org_study_id

2019-001227-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.